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The Parkinson’s disease protein LRRK2 impairs
proteasome substrate clearance without affecting
proteasome catalytic activity
M Lichtenberg1,2, A Mansilla1,2, VR Zecchini1,2, A Fleming1,2 and DC Rubinsztein*,1
Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common known cause of Parkinson’s disease (PD). The clinical
features of LRRK2 PD are indistinguishable from idiopathic PD, with accumulation of a-synuclein and/or tau and/or ubiquitin in
intraneuronal aggregates. This suggests that LRRK2 is a key to understanding the aetiology of the disorder. Although loss-of-
function does not appear to be the mechanism causing PD in LRRK2 patients, it is not clear how this protein mediates toxicity.
In this study, we report that LRRK2 overexpression in cells and in vivo impairs the activity of the ubiquitin-proteasome pathway,
and that this accounts for the accumulation of diverse substrates with LRRK2 overexpression. We show that this is not mediated
by large LRRK2 aggregates or sequestration of ubiquitin to the aggregates. Importantly, such abnormalities are not seen with
overexpression of the related protein LRRK1. Our data suggest that LRRK2 inhibits the clearance of proteasome substrates
upstream of proteasome catalytic activity, favouring the accumulation of proteins and aggregate formation. Thus, we provide a
molecular link between LRRK2, the most common known cause of PD, and its previously described phenotype of protein
accumulation.
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Parkinson’s disease (PD) is the second most common human
neurodegenerative disease. PD pathology involves loss of
dopaminergic neurons in the substantia nigra pars compacta
and other regions, and the formation of Lewy bodies (LB)
containing a-synuclein.1 Excessive a-synuclein is toxic, as
rare cases of inherited PD are caused by a-synuclein gene
triplication.2 However, the mechanisms causing a-synuclein
accumulation in sporadic PD are unclear.
Mutations in leucine-rich repeat kinase 2 (LRRK2), the most
common known cause of autosomal dominant PD, are also
found in ‘sporadic’ cases. The neurological and neurochem-
ical phenotypes are indistinguishable from the idiopathic form
of PD.3–5 Brains from PD patients with LRRK2mutations have
accumulation of a-synuclein and/or tau in intraneuronal
aggregates as well as ubiquitin-positive inclusions.3 This
variable pathology suggests that LRRK2 acts far upstream in
the PD neurodegeneration cascade.
The protein inclusions in PD patients may be due to failure
of the two major intracellular protein breakdown pathways, the
ubiquitin-proteasome system (UPS) and macroautophagy.
In the UPS, E1, E2 and E3 enzymes tag proteins with four or
more ubiquitin molecules, which target the substrate to the
proteasome, a barrel-shaped multiprotein complex with three
different protease activities that degrade substrates into
peptides. In macroautophagy, a double-layered membrane
forms around a portion of cytosol. This autophagosome fuses
with lysosomes, where its contents are degraded.
The LRRK2 protein has 2527 amino acids and several
independent domains, including three protein–protein-inter-
acting domains (ankyrin, LRR and WD40) and two enzymatic
activities (kinase and GTPase).6 The various mutations
associated with PD are found throughout the protein. Knock-
out studies in mice suggest that LRRK2 mutations confer
a gain-of-function.7,8 Initially, increased kinase activity was
considered as the pathogenic gain-of-function mechan-
ism.9,10 However, subsequent studies confirmed this finding
only for the commonest LRRK2 mutation, G2019S. Results
for other mutations have been contradictory and other toxic
effects may therefore exist.11
In this study, we investigated the role of LRRK2 in protein
homoeostasis. We observed a-synuclein and ubiquitin accu-
mulation in LRRK2-expressing cells and in a new LRRK2
zebrafish model. This imbalance in protein homoeostasis is
not only restricted to a-synuclein but can also affect a range of
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Figure 1 LRRK2 overexpression leads to increased protein levels. (a) GFP-tagged wild-type a-synuclein or (b) GFP-tagged A53T-a-synuclein was co-transfected in HeLa cells
with either empty vector, httQ23, WTLRRK2 or GSLRRK2. Increased GFP fluorescence was detected in cells overexpressing LRRK2 48 h post-transfection by flow cytometry. Left:
representative flow cytometry histograms show fluorescence intensity plotted against cell number. Increased fluorescence is observed in WTLRRK2- and GSLRRK2-transfected cells
(dark grey and light grey line, respectively), compared with cells transfected with vector (black line) or httQ23 (wild-type huntingtin exon 1, used as a control) (thin black line); right:
quantification of (a) and (b). Graphs show geometric mean of cellular fluorescence (normalised to vector-transfected cells within each experiment)±S.D. of all replicates. Unpaired,
two-tailed Student’s t-test was performed on raw replicate data from individual experiments and representative P-values are shown. ***Po0.005; ns¼ not significant, N¼ 3. (c and d)
Cell lysates from (a and b) were analysed by western blotting. Increased levels of GFP-tagged WT-a-synuclein and A53T-a-synuclein protein were detected in LRRK2-overexpressing
cells. (e) Immunoblot of LRRK2-overexpressing HeLa cell lysates showing an increase in the total amounts of ubiquitinated proteins compared with cells transfected with empty vector.
Lactacystin, a proteasome inhibitor, caused an even greater increase in ubiquitinated proteins than LRRK2. The lane for lactacystin was run on the same blot but next to other lysates,
which were cut from this picture. (f) Cortical neurons from E18 mouse brains were transfected with HA-httQ23 or Flag-WTLRRK2 and immunostained with antiubiquitin (green) and
antiHA (red) or antiFlag (red) antibodies, respectively. Representative images were taken with a Zeiss LSM510 confocal microscope. LRRK2 aggregates (open arrow heads) and
ubiquitin inclusions (filled arrow heads) do not always co-localise. Scale bars, 10mM. (g) Ubiquitin inclusions are more frequently observed in neurons expressing WTLRRK2 or
GSLRRK2, compared with cells expressing httQ23. Ubiquitin inclusion formation was assayed in three independent experiments. Representative data from one experiment are shown
as percentage of transfected cells with ubiquitin inclusions±S.D. and were analysed by unconditional logistical regression analysis. ***Po0.001, N¼ 3. See also Supplementary
Figure S1
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exogenous as well as endogenous proteins. Increased protein
levels were independent of protein production, sequestration
or impairment of autophagy but can be explained by UPS
compromise. The effect of LRRK2 on the UPS is independent
of its kinase activity, oxidative stress or p62. However,
preventing the aggregation of LRRK2 by HSP70 can modulate
the effect of LRRK2 on the UPS.
Results
Accumulation of a-synuclein and ubiquitin in LRRK2
overexpressing cells. PD is characterised by the
accumulation and aggregation of a-synuclein. We therefore
initially tested the effect of LRRK2 on a-synuclein levels. As
LRRK2 mutations are considered to cause toxicity through a
Figure 2 LRRK2 promotes httQ74 toxicity and accumulation of endogenous proteins. (a and b) COS-7 cells were co-transfected with the aggregate-prone protein httQ74-
EGFP along with LRRK2 (Flag) or httQ23. Cells were fixed 48 h after transfection and stained with an antibody against Flag and the nuclear dye DAPI. (a) Aggregation of
httQ74-EGFP and (b) cell death were scored in 200 cells per replicate. Graphs show means±S.E.M. of three independent experiments performed in triplicates. Statistical
analysis was performed by unconditional logistical regression analysis. ***Po0.001, N¼ 3. (c) HeLa cells were transiently co-transfected with GFP along with either empty
vector, httQ23, WTLRRK2 or GSLRRK2. After 48 h of transfection, cellular GFP fluorescence was measured by flow cytometry. Left: representative flow cytometry histogram
shows that GFP fluorescence was increased in HeLa cells that expressed WTLRRK2 or GSLRRK2 (dark grey and light grey line, respectively), compared with cells transfected
with vector or httQ23 (black and thin black line, respectively). Right: quantification of cellular fluorescence of three independent experiments performed in triplicates. The
geometric mean of cellular fluorescence was normalised to vector-transfected cells within each experiment, error bars represent standard deviation of all replicates. Unpaired,
two-tailed Student’s t-test was performed on raw replicate data from each individual experiment and representative P-values are shown. ns¼ not significant, ***Po0.005,
N¼ 3. (d) HeLa cells were transiently co-transfected as in (c). Additionally, the effect of LRRK1 overexpression was tested on levels of GFP. Overexpression of LRRK2 but not
LRRK1 or httQ23 lead to increased fluorescence, compared with vector-transfected cells. Graph represents data as above from three independent experiments performed in
triplicates (N¼ 3). (e) The human neuroblastoma cell line SHSY5Y was transfected and analysed as HeLa cells in (d). Increased GFP fluorescence was measured in cells
transfected with LRRK2, but not in httQ23- or LRRK1-transfected cells. Graph represents data as above from four independent experiments performed in triplicates (N¼ 4).
(f) HeLa cells were transfected with GFP and DsRed and either control DNA or LRRK2. After 48 h of transfection cells were sorted for GFP and DsRed double-positives and
grown for 24 h before cell collection. An additional vector control was treated for 12 h with MG132, a proteasome inhibitor, before collection. p53 levels were analysed by
western blotting. Left: blots represent one of seven independent experiments. Densitometry results beneath the blots are normalised to actin. Right: quantification of seven
independent experiments. Data are normalised to vector-transfected cells and graphs show mean±S.D. Raw data were analysed by two-tailed, paired Student’s t-test.
*Po 0.05, **Po0.01, N¼ 7. Note, that MG132 treatment was only performed in two of the seven experiments
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gain-of-function mechanism, we studied the effects of
LRRK2 overexpression.
HeLa cells were transfected with either wild-type (WT) or
A53T-mutant GFP-tagged a-synuclein (which causes rare
forms of autosomal dominant PD). Simultaneously, cells were
transfected with wild-type (WTLRRK2) or G2019S-mutant
(GSLRRK2) Flag-tagged LRRK2, or vector DNA as a control.
The G2019S mutation in LRRK2 is the most common cause of
hereditary PD and is considered toxic due to excessive kinase
activity.12 As an additional control, we included httQ23, the
non-pathogenic exon 1 of wild-type huntingtin protein contain-
ing 23 glutamine repeats, which was used to control for
possible effects due to exogenous protein expression. Both
WTLRRK2 and GSLRRK2 overexpression led to increased
levels of WT and A53T-mutated overexpressed a-synuclein
(Figures 1a–d).
Besides an increase in a-synuclein levels, accumulation of
ubiquitinated proteins is also described in LRRK2 PD.3
Interestingly, we observed that overexpression of both
WTLRRK2 and GSLRRK2 increased the ubiquitinated
proteins in HeLa cells and mouse primary cortical neurons
(Figures 1e–g and Supplementary Figure S1). We studied
cortical neurons, as LRRK2 is significantly expressed in this
region, where inclusion pathology has been observed.3 As
previously described, overexpression of LRRK2 resulted in
the formation of LRRK2 aggregates.13,14 However, these
rarely co-localised with ubiquitin inclusions (Figure 1f and
Supplementary Figure S1), suggesting that the observed
increase in ubiquitin inclusion formation was not caused by
the sequestration of ubiquitin in LRRK2 aggregates.
LRRK2 affects a-synuclein and other proteins. To test if
LRRK2 had more general effects on protein homoeostasis,
we tested whether its overexpression had an effect on
another protein that aggregates intracellularly. Mutant
polyglutamine-expanded huntingtin fragment (httQ74) is an
aggregate-prone protein that rapidly forms inclusions after
transfection in cells and leads to cell death. In this study, we
have used the mutated polyglutamine protein as an
exogenous ‘reporter’ for protein homoeostasis. LRRK2
Figure 3 Increased protein levels due to LRRK2 overexpression are not a function of transcription or translation. (a) qRT-PCR analysis of mRNA levels of overexpressed
GFP-tagged a-synuclein and (b) mRNA levels of overexpressed GFP in HeLa cells transfected with WTLRRK2, GSLRRK2 or vector. mRNA levels are normalised to GAPDH.
Graphs show data from two independent experiments performed in triplicate. Data are shown as means (normalised to vector-transfected cells)±S.D. of replicates. Statistical
analysis was performed on raw replicate data within each experiment by two-tailed, unpaired Student’s t-test and representative P-values are shown. ns¼ not significant,
*Po0.05, **Po0.01, N¼ 2. (c) Degradation of b-catenin is slowed in LRRK2-transfected cells. HeLa cells were transfected with LRRK2 or control DNA. After 48 h of
transfection, protein synthesis was inhibited by treatment with CHX for the indicated time (minutes). Degradation of b-catenin was assessed by western blot. (d) Quantification
of (c). Graph shows data from three independent experiments as means (normalised to vector-transfected cells at time point zero)±S.E.M. Statistical analysis was performed
on normalised data by two-tailed, paired Student’s t-test. ns¼ not significant, *Po0.05, N¼ 3
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overexpression increased the percentage of transfected
COS-7 cells with httQ74GFP aggregates and cell death
(Figures 2a and b). To assess the specificity of this effect, we
also tested the effect of LRRK1 on httQ74 aggregation.
Overexpression of LRRK1, a paralogue of LRRK2 that has a
very similar domain structure,15 did not affect httQ74
aggregation in COS-7 cells (Supplementary Figure S2A),
suggesting that this effect is specific to PD-associated
LRRK2.
Importantly, LRRK2 aggregates do not co-localise with
httQ74 aggregates (Supplementary Figure S2B), suggesting
that LRRK2 does not sequester httQ74 but promotes its
aggregation by other means. Such an increase in the number
of aggregate-containing cells can occur either because of a
specific increase in aggregation or due to other factors, as
httQ74 aggregation is concentration-dependent.16
To further assess the specificity of the LRRK2 effect on
protein homoeostasis, we measured levels of GFP in cells
Figure 4 LRRK2 overexpression interferes with the UPS but not with proteasome catalytic activity. (a) Increased levels of GFP-tagged A53T-a-synuclein in Atg5þ /þ and
Atg5-/- MEFs in response to LRRK2 overexpression. Atg5þ /þ and Atg5-/- MEFs were transfected with WTLRRK2, GSLRRK2 or empty vector and co-transfected with GFP-
tagged A53T-a-synuclein. GFP fluorescence was measured 48 h after transfection by flow cytometry and normalised to vector controls. Graph shows data from four
independent experiments performed in triplicates as normalised means±S.D. of replicates. Statistical analysis was performed on raw replicate data of each individual
experiment by two-tailed, unpaired Student’s t-test and representative P-values are shown. ns¼ not significant, **Po0.01, ***Po0.001, N¼ 4. (b) The UPS-specific reporter
UbG76V–GFP was overexpressed in HeLa cells along with LRRK2 or vector. Immediately after transfection, cells were treated with the proteasome inhibitor MG132 (10mM) or
vehicle (DMSO), and GFP fluorescence was measured 12 h later by flow cytometry. Increased levels of fluorescence were measured in LRRK2-transfected, vehicle-treated
cells, compared with vector-transfected, vehicle-treated cells. Treatment with MG132 increased levels of fluorescence in all samples, and no difference was detected between
LRRK2- and vector-transfected cells in the presence of MG132. Graph shows data from three independent experiments performed in triplicates (normalised to vector-
transfected, DMSO-treated cells) as means±S.D. of replicates. Statistical analysis was performed on raw replicate data of each individual experiment by two-tailed, unpaired
Student’s t-test and representative P-values are shown. ns¼ not significant, **Po0.01, N¼ 3. (c) HeLa cells were transfected and treated as in (b). Protein levels were
measured by western blotting 12 h after transfection. Increased UbG76V–GFP protein levels are measured in response to LRRK2 overexpression in vehicle-treated, but not in
MG132-treated cells, compared with the respective vector control. Blot shown is representative for four independent experiments. Asterisk (*) indicates unspecific band. (d–f)
Proteasome catalytic activities in HeLa cell lysates transfected with GFP and LRRK2, httQ23 or vector. GFP-positive cells were sorted 48 h post-transfection and proteasome
activity was analysed by a fluorigenic in vitro assay. As a control, proteasome activities were also measured in vector-transfected lysates treated with MG132. Data from three
independent experiments are shown as means (normalised to vector-transfected cells)±S.D. of replicates. Statistical analysis was performed on raw replicate data by two-
tailed, unpaired Student’s t-test and representative P-values are shown. ns¼ not significant, N¼ 3. (g) Cell lysates from the same conditions as in a–c were immunoblotted
with antibodies against the indicated proteasome subunits. Blots are representative for three independent experiments (N¼ 3). See also Supplementary Figure S4
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overexpressing LRRK2 and found this to be increased
(Figure 2c). As the aggregate-prone protein httQ74 did not
increase GFP fluorescence (Supplementary Figure S2C), this
suggests that the increase in GFP fluorescence caused by the
overexpression of LRRK2 is not a generic effect of aggregate-
prone proteins, and may indicate that GFP and other proteins
are not simply sequestered in LRRK2 aggregates. LRRK2
overexpression also caused an increase in GFP fluorescence
in a neuroblastoma cell line, while LRRK1 did not affect
GFP fluorescence, suggesting that the observed effect on
protein levels is specific for the PD-associated LRRK2
(Figures 2d and e).
We also tested the effect of LRRK2 on levels of an
endogenous protein. As shown in Figure 2f, levels of p53 (a
well-characterised proteasome substrate17) were elevated in
LRRK2-transfected cells. Together, these results suggest that
the effect of LRRK2 is not only specific for overexpressed
a-synuclein but can also cause the accumulation of endogen-
ous as well as other exogenous intracytosolic proteins.
LRRK2 acts independently of transcription or trans-
lation. It has been previously described that WTLRRK2
overexpression can increase WT-a-synuclein mRNA and
protein levels through ERK pathway activation in HEK293
cells.18 However, we did not observe ERK activation in our
cells (Supplementary Figure S3). Furthermore, we confirmed
that LRRK2 overexpression did not affect transcription of
GFP-tagged a-synuclein or GFP, suggesting that the
increased protein levels due to LRRK2 overexpression is not
caused by increased protein synthesis (Figures 3a and b).
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We next determined whether the effects of LRRK2 on
protein levels were dependant on translation. In cells
transfected with empty vector, levels of the proteasome
substrate b-catenin decreased over 60 min of treatment with
cycloheximide due to blocked translation and continuing
degradation. b-catenin levels decayed more slowly in cells
transfected with LRRK2, suggesting that it increases protein
levels via impairment of degradation rather than upregulation
of protein synthesis (Figures 3c and d).
Expression of LRRK2 interferes with the UPS. The
proteins that we have so far shown to be affected by
LRRK2 overexpression can be degraded by both the UPS
and macroautophagy, although with different preferences
(Supplementary Figure S4A). We next investigated the effect
of LRRK2 overexpression on levels of A53T-a-synuclein and
GFP in Atg5-/- autophagy- incompetent and matched-wild-type
mouse embryonic fibroblasts (MEFs, 19). A53T-a-synuclein
and GFP were increased in these matched cell lines (Figures
4a and b), suggesting that the protein accumulation due to
LRRK2 overexpression was autophagy independent.
We next aimed to assess the role of the UPS in LRRK2-
mediated protein accumulation. Proteins are targeted for
proteasomal degradation after they are tagged with ubiquitin
chains, and we used an artificial proteasome substrate where
ubiquitin is N-terminally fused to GFP (UbG76V–GFP).20 Under
normal conditions, this modified GFP is quickly degraded and
hardly detectable. However, impaired UPS function can be
sensitively detected by increased levels of this reporter.17,20
LRRK2 overexpression caused increased UbG76V–GFP
levels (Figures 4b and c, Supplementary Figure S4C) without
affecting transcription (Supplementary Figure S4D), suggest-
ing that LRRK2 interferes with UbG76V–GFP degradation by
the UPS. Importantly, proteasome inhibition with MG132 led
to a similar accumulation of UbG76V–GFP fluorescence
(Figure 4b) and protein (Figure 4c) in LRRK2- and control-
transfected cells, suggesting that LRRK2 overexpression
affects protein homoeostasis by impairing the UPS.
We further tested the role of the proteasome by performing
in vitro assays in cell lysates to measure the three catalytic
activities of the proteasome active sites. While all three
catalytic activities were unaffected by LRRK2 overexpression
(Figures 4d–f), it is important to note that this assay is
independent of upstream processes like ubiquitination and
deubiquitination.
We further showed that expression levels of various
proteasome subunits were unaffected by LRRK2 overexpres-
sion (Figure 4g). Together, these results suggest that LRRK2
overexpression causes protein accumulation via UPS impair-
ment, but does not affect the protein levels or the catalytic
activities of the proteasome itself.
Effect of LRRK2 on protein levels is independent of its
toxicity. It has been previously shown that mutant LRRK2
is toxic when transfected into neurons or neuroblastoma
cell lines, leading to neurite process reduction and
apoptosis.13,14,21 We therefore investigated whether cell
death caused by LRRK2 overexpression affected protein
accumulation. We confirmed a cytotoxic effect of LRRK2
overexpression on HeLa cells compared with LRRK1 and
httQ23 (Supplementary Figures S5A and B). As previously
shown, cell death due to LRRK2 overexpression coincided in
most cells with caspase 3 activation (Supplementary Figures
S5B and C).21 Indeed, the caspase inhibitor Z-VADfmk
reduced the activation of caspase 3 caused by LRRK2
overexpression, and this coincided with reduced cell death 21
(Supplementary Figures S5A–C). The accumulation of GFP
fluorescence due to LRRK2 overexpression was, however,
not diminished in the presence of antiapoptotic and
antioxidant (NAC) drugs (Figures 5a and b). Together, the
Figure 5 The increase in protein levels is not due to oxidative stress, increased cell death, kinase activity or p62. (a) HeLa cells were transfected with empty vector,
WTLRRK2, GSLRRK2 or httQ23, and co-transfected with GFP as a reporter protein. Cells were treated immediately after transfection with the caspase inhibitor Z-VADfmk and
GFP fluorescence intensity was measured by flow cytometry 48 h after transfection. The increase in GFP fluorescence in response to LRRK2 overexpression was not
prevented by caspase inhibition. (b) Cells were transfected as in (a) and treated immediately after transfection with the antioxidant N-acetyl-L-cysteine (NAC). Cellular GFP
fluorescence was measured 48 h later by flow cytometry. The increase in fluorescence due to LRRK2 overexpression was not prevented by treatment with NAC. (c) HeLa cells
were transfected as in (a) and treated with 250 nM K252a or DMSO for 48 h. Cellular GFP fluorescence was measured 48 h later by flow cytometry. The increase in
fluorescence due to LRRK2 overexpression was not prevented by treatment with the LRRK2 kinase inhibitor. (a–c) All graphs show means of normalised data±S.D. of
replicates from three independent experiments. Statistical analysis was performed on raw replicate data by two-tailed, unpaired Student’s t-test and representative P-values
are shown. ns¼ not significant, ***Po0.001, N¼ 3; black symbols reflect P-values compared with DMSO-treated cells, grey symbols reflect P-values compared with drug-
treated cells. Note, that data shown in graph 6D for untreated cells are the same data as in Supplementary Figure S2B, where httQ74 was included. (d) HeLa cells were
transfected with WTLRRK2 or KMLRRK2 or vector DNA, and cell lysates were analysed 48 h after transfection by western blotting. Similar levels of WTLRRK2 and KMLRRK2
protein were detected. (e and f) HeLa cells were transfected as in (d), and co-transfected with GFP. GFP fluorescence was measured 48 h after transfection by flow cytometry.
(e) Increased levels of GFP fluorescence were detected in both WTLRRK2- and KMLRRK2-transfected cells (dark grey and light grey line, respectively), compared with vector-
transfected cells (black line). (f) Graph shows data normalised to vector-transfected cells for three independent experiments performed in triplicates as means±S.D. of
replicates. Statistical analysis was performed on raw replicate data by two-tailed, unpaired Student’s t-test and representative P-values are shown. ***Po 0.001, N¼ 3.
(g) HeLa cells transfected with GFP and DsRed were co-transfected with LRRK2 or control DNA. p62 protein levels were assessed by western blotting 48 h later following
FACS sorting for double-positive cells and a recovery period of 24 h. Blot is the same blot as shown in Figure 4g and representative for three independent experiments.
(h) Quantification of (g). Data normalised to vector-transfected cells are shown for three independent experiments as means±S.D. Statistical analysis was performed on raw
data by two-tailed, paired Student’s t-test. ns¼ not significant, N¼ 3. (i) Knockdown of p62. HeLa cells were twice transfected with 50 nM siRNA targeted against p62. p62
levels were assessed by western blot 48 h after the second knockdown. (j and k) HeLa cells were transfected with siRNA targeted against p62 as in (i). GFP and LRRK2 or
control DNA was co-transfected at the second knockdown. GFP fluorescence was measured by flow cytometry 48 h after the second transfection. (j) Representative flow
cytometry histograms show fluorescence intensity plotted against cell number. Left: in the presence of non-targeting control siRNA, increased fluorescence is observed in
response to WTLRRK2 and GSLRRK2 overexpression (dark grey and light grey line, respectively), compared with vector- or httQ23-transfected cells (thick and thin black line,
respectively). Right: in the presence of p62-targeting siRNA, the same increase in cellular fluorescence as with control siRNA is observed in LRRK2-transfected cells. (k)
Graph shows data (normalised to vector-transfected cells) from four independent experiments performed in triplicates as means±S.D. Statistical analysis was performed on
raw replicate data by two-tailed, unpaired Student’s t-test and representative P-values are shown. ns¼ not significant, ***Po0.001, N¼ 4
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above data suggest that the accumulation of various proteins
after LRRK2 overexpression is not a consequence of
caspase activation or reactive oxygen species.
LRRK2 effect on protein levels is independent of its
kinase activity. Some studies investigating LRRK2
toxicity revealed a critical role for the kinase domain,
supporting a gain-of-function effect due to the the increased
kinase activity.12,13,22 We therefore investigated whether the
kinase activity of LRRK2 is relevant for its observed effect on
protein accumulation. As shown in Figure 5c and
Supplementary Figure S5D, the increase in GFP levels
caused by LRRK2 overexpression was not reduced by
two published LRRK2 kinase inhibitors.23,24 Furthermore,
the artificial kinase-dead mutation construct K1906M
(KMLRRK2)10 also increased GFP fluorescence similarly to
WTLRRK2 (Figures 5d–f). In conclusion, the effect of LRRK2
on protein levels seems to occur independently of the kinase
activity.
Accumulation of proteins upon LRRK2 expression is
independent of p62. We have recently shown that
overexpression of the ubiquitin-binding protein, p62, inhibits
degradation of substrates destined for the proteasome at a
step upstream of proteasome catalytical activity,17 resulting
in a very similar phenotype to that described in this study.
In the present study LRRK2 overexpression itself did not
affect endogenous levels of p62 (Figures 5g and h). In order
to test if the effect of LRRK2 on the UPS was p62 dependent,
we reduced p62 levels by transfecting p62 siRNA into HeLa
cells (Figure 5i), and tested the effect of LRRK2
overexpression on levels of GFP as before by flow
cytometry. In the presence of control siRNA, LRRK2 led to
an increase of GFP fluorescence as described before
(Figure 2). This increase was not affected by siRNA
directed against p62 (Figures 5j and k), suggesting that
p62 is not involved in the impairment of the UPS by LRRK2.
Co-expression of HSP70 enhances the effect of LRRK2
on protein accumulation. HSP70 is a chaperone that
Figure 6 The increase in protein levels can be modulated by HSP70. (a) COS-7 cells transfected with WTLRRK2 or GSLRRK2 were co-transfected with either vector or
HSP70 in a molar ratio of 1 : 2 (LRRK2/HSP70). Cells were fixed 24 h post-transfection, stained with antiFlag antibody, and LRRK2 aggregates were scored in at least 200
cells per replicate. Graph shows mean percentage of cells containing LRRK2 aggregates±S.E.M. from three independent experiments. Statistical analysis was performed by
unconditional logistical regression analysis. ***Po0.001, N¼ 3. (b and c) HSP70 co-expression enhances the accumulation of GFP protein in response to LRRK2
overexpression. HeLa cells were transfected with WTLRRK2, GSLRRK2, vector or httQ23 and co-transfected with GFP. Additionally, cells were transfected with vector or
HSP70. Molar ratio of LRRK2/HSP70 is 1 : 2. Cells were treated immediately after transfection with DMSO or Z-VADfmk. GFP fluorescence was measured 48 h post-
transfection by flow cytometry. (b) Representative flow cytometry histograms show increased cellular GFP fluorescence in response to WTLRRK2 and GSLRRK2
overexpression (dark and light grey line, respectively), compared with cells transfected with vector or httQ23 (thick and thin black line, respectively). This increase in
fluorescence is enhanced when HSP70 is co-overexpressed (right histogram). (c) Quantification of (b). Graph shows data (normalised to vector-transfected cells) from three
independent experiments performed in triplicates as mean±S.D. of replicates. Statistical analysis was performed by two-tailed, unpaired Student’s t-test on replicates of
individual experiments and representative P-values are shown. ns¼ not significant, ***Po0.001, N¼ 3
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assists folding of misfolded proteins, and LRRK2 has been
described as an aggregating protein. Both WTLRRK2 and
GSLRRK2 aggregation are decreased by overexpressed
HSP70 (Figure 6a). Accordingly, we tested whether co-
expression of HSP70 affected the LRRK2-mediated
accumulation of GFP. We overexpressed LRRK2 along
with GFP and either control DNA or HSP70 and measured
GFP fluorescence. HSP70 overexpression enhanced the
GFP increase mediated by LRRK2 overexpression (Figures
6b and c). This was also seen in the presence of the anti-
apoptotic drug Z-VADfmk (Figures 6b and c), suggesting that
HSP70 acts on LRRK2-mediated protein accumulation
through a mechanism other than its anti-apoptotic effect.25
Interestingly, HSP70 overexpression had no significant
effect on soluble LRRK2 levels (Supplementary Figures S6A
and B). As HSP70 decreases LRRK2 aggregation and
enhances its effect on protein levels, the accumulation of
proteins caused by LRRK2 is not simply due to its aggrega-
tion. Instead, our data suggest that LRRK2 is more accessible
in the presence of HSP70, for example, as mono- or
oligomeric forms, and that these species may mediate the
accumulation of other proteins.
LRRK2 affects protein accumulation in vivo. To confirm
the in vivo relevance of our observations, we performed
transient DNA overexpression experiments in zebrafish
(Figure 7a). Transient co-expression of WTLRRK2 or
GSLRRK2 with UbG76V–GFP caused a significant increase
in the number of embryos with mosaic GFP expression,
compared with co-expression of UbG76V–GFP with LRRK1
or the vector control constructs (Figures 7b and c), which
we confirmed by western blot (Figure 7d). Together, these
results demonstrate that clearance of transiently expressed
UbG76V–GFP is impaired when co-expressed with WTLRRK2
Figure 7 LRRK2 expression causes UPS disruption in zebrafish. (a) LRRK2 expression in zebrafish. Zebrafish embryos were injected with empty vector or WTLRRK2 at
the 1–2 cell stage and lysed at 12 h.p.f. LRRK2 protein was detected by western blotting. Asterisk indicates unspecific band; arrow indicates LRRK2 band. (b) Zebrafish
embryos at 12 h.p.f. following injection of UbG76V–GFP with either WTLRRK2 (I & IV) or empty vector (II & V). Uninjected siblings (III & VI) are included for comparison. Injection
of WTLRRK2 (IV) or GSLRRK2 (not shown) resulted in a high and stable level of UbG76V–GFP expression. Typically, expression was observed in more than 30 cells. Injection
of LRRK1 (not shown) or vector (V) resulted in a low level of UbG76V–GFP expression. In vector- and LRRK1-injected embryos, expression was observed in less than 10 cells
per embryo. (c) Quantification of (b). Graph represents data of three independent experiments as mean percentage of fish with UbG76V–GFP-positive cells±S.D. Statistical
analysis was performed by two-tailed, unpaired Student’s t-test. **Po0.01, ***Po0.001, N¼ 3. (d) Increased levels of UbG76V–GFP were detected in WTLRRK2-expressing
zebrafish by western blot. Asterisk (*) indicates unspecific band; arrow indicates LRRK2 band
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or GSLRRK2, suggesting that overexpression of LRRK2
causes disruption of the UPS in vivo.
Discussion
PD patients with LRRK2 mutations have pleiomorphic
pathology, where a-synuclein and/or tau and/or ubiquitin have
been detected in intraneuronal aggregates.3 Furthermore, the
phenotype of LRRK2 PD is very similar to the idiopathic PD.3,5
Accordingly, it is believed that LRRK2 acts far upstream in the
unknown pathway leading to the development of the disease,
and that deciphering the roles of LRRK2 will provide
significant insight into PD pathogenesis of PD.
The abnormal accumulation of cytoplasmic inclusions
with ubiquitin is a common feature in PD and other
neurodegenerative diseases. This could arise if an inter-
ference with protein degradation was one of the principal
mechanisms leading to the development of the diseases. Our
data demonstrate the involvement of LRRK2 in protein
homoeostasis. We have provided a mechanism for the
accumulation of multiple proteins due to LRRK2 overexpres-
sion by showing that this results in impaired flux through the
UPS. This would result in the accumulation a-synuclein, tau
and ubiquitin in PD patients with LRRK2 mutations, if the
disease is due to excess LRRK2 function, as has been
proposed.7,8 Our data are further supported by the observa-
tion that LRRK2 overexpression enhances ubiquitin accumu-
lation in mice.7
Our data suggest that UPS malfunction is the major cause
behind the accumulation of proteins in this context, as LRRK2
overexpression resulted in no additional protein reporter
protein accumulation in proteasome-inhibited cells (Figure 4).
Furthermore, LRRK2 overexpression led to protein accumu-
lation in autophagy-incompetent cells (Figure 4), suggesting
that the effects are autophagy-independent. The idea of UPS
impairment by LRRK2 is further supported by the accumula-
tion of a specific proteasome substrate in both LRRK2-
expressing cells and zebrafish (Figure 7).
We have shown that LRRK2 did not affect the catalytic
activity of the proteasome or expression levels of proteasomal
core subcomplexes (Figure 4). Moreover, co-expression of
HSP 70 decreased the tendency of LRRK2 to form aggre-
gates and at the same time enhanced LRRK2-mediated
protein accumulation (Figure 6). Together, these findings
suggest that accumulation of proteins after LRRK2 expres-
sion is not caused by sequestration of these proteins or
proteasomal subunits into LRRK2 aggregates, but rather by
mono- or oligomeric forms of LRRK2 acting on the UPS. It is
not clear at which level the UPS is perturbed by LRRK2. The
cascade of reactions acting upstream of the proteasome
catalytic activity is complex and finely tuned. It is possible that
ubiquitination or de-ubiquitination may be perturbed or that
recognition or transport of ubiquitinated proteins to the
proteasome may be altered.
Disease-causing LRRK2 mutations are found throughout
the protein. Although increased kinase activity was consis-
tently shown for the most prominent G2019S mutation, data
for other mutations are contradictory.11,26 Thus, mutant
LRRK2 may confer pathogenic effects through other func-
tions. In our experimental conditions, the wild-type form
of LRRK2 had a significant effect on reporter protein levels
and ubiquitin levels that were similar to G2019S-mutated
LRRK2. Also, chemical or genetic inhibition of LRRK2 kinase
activity did not modulate the accumulation of proteins,
suggesting that LRRK2 kinase activity is not a major
determinant of its UPS-inhibitory phenotype. This is sup-
ported by in vivo data.27
Mutations in LRRK2 cause PD through a gain-of-function
mechanism, and we therefore overexpressed the protein in
order to mimic a gain-of-function. Although the kinase activity
does not seem to be critical for the impairment of the UPS
system, it is surprising that the G2019S mutation does not
confer additional toxicity compared with WTLRRK2. It is
feasible that a kinase-independent toxic mechanism depends
on exceeding a threshold level of activity, which may be
lowered by pathogenic mutations. This kind of mechanism is
supported by the finding that homo- and heterozygous
carriers of LRRK2 mutations are clinically indistinguishable.28
If we assume that LRRK2 function needs to exceed a
threshold level in order to become toxic, then this may explain
why we could not observe a difference in the effect of
WTLRRK2 and GSLRRK2 on the impairment of the UPS in an
overexpression study.
Alternatively, we may have missed a small but biologically
significant difference in effect. The overexpression of LRRK2
may result in a saturated environment where target proteins or
auxiliary factors become rate limiting and therefore reduce the
true effect size. Even if these other proteins are in abundance,
overexpression might over-represent the impact of the protein
to such an extent that small differences are not detectable.
However, even a small difference may have deleterious
consequences over the course of a lifetime, as in PD.
Lastly, we cannot exclude the possibility that UPS inhibition
is a wild-type function of LRRK2 unrelated to PD. Although we
do not consider this a likely scenario, we believe the
involvement of LRRK2 with the UPS as relevant, as it provides
some insights into LRRK2’s function, which is poorly under-
stood. It is also critical to understand the consequences of
LRRK2 overexpression for understanding models of LRRK2
PD, as all Drosophila,29–31 mouse7,32,33 and cell-
based9,12,13,21,22,34–36 models published to date have relied
on overexpression.
Altogether our data support a role for LRRK2 in the UPS
pathway. It is possible that the accumulation of UPS substrates
in LRRK2-mediated PD may be caused by a similar mechanism
to LRRK2 overexpression, consistent with a gain-of-function
model. A better knowledge of the function of LRRK2 will assist
further generation of cellular and animal models and allow for the
development of rational therapeutic strategies.
Materials and Methods
Plasmids. Flag-tagged wild-type LRRK2 (WTLRRK2) and G2019S mutant
(GSLRRK2) were kindly provided by CA Ross,37 the K1906M LRRK2 mutant was
generated from a myc-tagged wild-type LRRK2 construct kindly provided by M
Cookson.36 The LRRK1 construct was kindly provided by D Korr.15 HD gene exon 1
fragment with 74 or 23 polyQ repeats in pEGFP-C1 (Clontech, Palo Alto, CA, USA)
or in pHM6 (Roche Diagnostics, Mannheim, Germany) and pEGFP-a-synuclein
A53T or wild-type a-synuclein in pEGFP-C1 were described previously.16,38
Plasmid pEGFP-UbG76V (UbG76V–GFP) was kindly provided by N Dantuma.20
DsRed-C1 (DsRed) was from Clontech and pCDNA3.1 was from Invitrogen
(Carlsbad, CA, USA).
PD-associated protein LRRK2 impairs UPS
M Lichtenberg et al
10
Cell Death and Disease
Cell culture, transfections and flow cytometry analysis. HeLa,
SHSY5Y and COS-7 cells were grown in DMEM medium (Sigma, St. Louis, MO,
USA) supplemented with 10% foetal calf serum, penicillin/streptomycin and 2 mM L-
glutamine at 371C in 5% CO2. This medium was supplemented with 5 mg/ml
geneticin (Sigma) for the culture of the UbG76V–GFP-expressing stable cell line (kind
gift from NP Dantuma). PC12 cells were grown in DMEM medium supplemented
with 10% horse serum, 5% foetal calf serum (Sigma), penicillin/streptomycin
(Sigma) and 2 mM L-glutamine (Sigma) at 371C in 10% CO2. PC12 cells were
differentiated by the addition of 1 mM NGF (Upstate, Milton Keynes, UK) for 5 days
before transfection. Transfections were performed using Lipofectamine Plus or
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
For primary neuron cultures, cortex was dissected from E18 mouse embryo
brains in DMEM containing pyruvate, 4.5 g/l glucose and L-glutamine. The tissue
was triturated to a single-cell suspension using a 200-ml pipette until no pieces could
be seen. Cells were then plated at the desired density on poly-D-lysine-coated
coverslips in DMEM containing 2% B-27 (Invitrogen), 1% PSF and 1% foetal calf
serum. The cells were transfected with Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions.
For flow cytometry cells were transfected with a GFP-containing reporter protein
and analysed with FACS Calibur 48 h after transfection. Data represent the
geometric mean of green intensity.
For cell sorting experiments, HeLa cells were transfected with both GFP and
DsRed, and either control or WTLRRK2 or GSLRRK2 DNA in a molar ration of
1 : 10. Cells were sorted 48 h after transfection for GFP and DsRed double-positive
cells based on the assumption that double-transfected cells are more likely to be
also transfected with LRRK2 or control DNA than cells that were not or only single
transfected. We thus isolated cell populations that were enriched in triple-
transfected cells, expressing GFP and DsRed and either httQ23, WTLRRK2 or
GSLRRK2. These cells were grown for an additional 24 h in order to recover from
the sorting process. Cells were then harvested and lysates were analysed by
western blot.
Aggregation assay. After 24 or 48 h transfection aggregates were scored
using a Zeiss Axiophot fluorescence microscope (Zeiss, Jena, Germany) with a  25
objective. At least 200 transfected cells in triplicate were counted in each case.
Translation. HeLa cells were transfected with vector or LRRK2 DNA. After 48 h
of the transfection, cells were treated with 50 mg/ml cycloheximide (Sigma) for up to
60 min and then harvested for western blot analysis.
Transcription. HeLa cells were co-transfected with GFP and DsRed and either
vector or LRRK2 DNA. GFP and DsRed double-positive cells were sorted and RNA
was extracted using TRIZOL (Invitrogen). cDNA was generated using Superscript III
Kit (Invitrogen) and qRT-PCR was performed with SYBR PCR mix (Applied
Biosystems, Foster City, CA, USA) using the following primers: GFP: 50-ATGG
TGAGCAAGGGCGAGGAGCT-30 (forward) 50-GAAGATGGTGCGCTCCTGG
ACGT-30 (reverse); GAPDH: 50-TGTGTCCGTCGTGGATCTGA-30 (forward)
50-CCTGCTTCACCACCTTCTTGAT-30 (reverse); actin: 50-AGAAAATCTGGC
ACCACACC-30 (forward) 50-GGGGTGTTGAAGGTCTCAAA-30 (reverse).
Caspase and kinase inhibitors and antioxidant treatment. .Caspase
inhibitors Ac-YVAD-cho, Z-VAD-fmk and Z-DEVD-fmk (Calbiochem, Darmstadt,
Germany) were used at a final concentration of 20 mM in DMSO. The antioxidant N-
Acetyl-L-cysteine (NAC) (Sigma) was dissolved in medium (DMEM), the pH
adjusted to 7.4 and used at 1 mM final concentration. Cells were treated after
transfection and the treatment was replaced after 24 h. For the determination of
condensed nuclei and caspase 3 activation, cells were fixed 48 h after transfection
and stained with an active caspase 3 antibody (Promega, Madison, WI, USA,
1 : 250). At least 200 transfected cells were scored using a Zeiss Axiophot
fluorescence microscope with a  63 oil objective. Cells were treated with LRRK2
kinase inhibitors K252a (250 nM) and Raf1 kinase inhibitor I (2mM) immediatedly
after transfection for 48 h, followed by flow cytometry.
Immunocytochemistry (ICC) and western blotting (WB). For ICC,
cells were grown on coverslips coated with poly D-lysine (Sigma) and fixed for
10 min in 4% paraformaldehyde at room temperature. The cells were then
permeabilised for 10 min in 1XPBS with 2% Triton-X100, washed in 1XPBS and
blocked in 1XPBS containing 1% BSA and 10% goat serum for 1 h at room
temperature. Primary antibodies (antiFLAG 1 : 500 Sigma, antiHA 1 : 500 Sigma
and antiubiquitin 1 : 500 Sigma) were diluted in 1XPBS with 1%BSA and incubated
overnight at 41C. The cells were washed in 1XPBS and incubated with the
fluorescent Alexa-conjugated secondary antibody (1 : 500 all Invitrogen) for 1 h at
room temperature. After two more washes, the coverslips were mounted in Fluocity
containing DAPI. Images were taken with a Zeiss LSM510 confocal microscope
using a  63 oil objective and analysed by Adobe Photoshop CS4 (Adobe,
San Jose, CA, USA).
For WB, cells were sorted (Dako Cytomation MoFlo, Glostrup, Denmark) 48 h after
transfection, unless otherwise indicated, harvested in RIPA buffer containing protease
and phosphatase inhibitors (Roche). Protein content was determined using Bio-Rad
(Hercules, CA, USA) Protein Assay kit and the proteins were separated by SDS-
PAGE. The blots were incubated with antibodies to antiGFP (Sigma 1 : 2000),
antiactin (Sigma, 1 : 1000), antitubulin (Sigma, 1 : 10000), antiubiquitin (Chemicon,
Rosemont, IL, USA, 1 : 5000), antiFlag (Sigma 1 : 1000) antiHA (Covance, Princeton,
NJ, USA, 1 : 2000), antia-synuclein (Abcam, Cambridge, UK) antiLC3 (Novus
Biologicals, Cambridge, UK, 1 : 2000), antiUbiquitin (Sigma, 1 : 5000), antiRpt5,
antiRpn10, antia4 and anti 20S (Biomol, Exeter, UK, 1 : 1000) in 5% non-fat milk. The
signal after the incubation with the secondary antibodies (antimouse-HRP or
antirabbit-HRP Roche 1 : 10000) was detected by autoradiography using the
Amersham (GE Healthcare, Little Chelfont, UK) chemiluminescent substrate.
Proteasome assay. Cells transfected with LRRK2, DsRed and GFP were
sorted by FACS 48 h after transfection. DsRed and GFP double-positive cells were
retained and lysed in UPS activity buffer (10 mM Tris HCl pH 7.5; 1 mM EDTA; 20%
glycerol; 2 mM ATP; 0.5% Triton-X 100; protease inhibitor (Roche)). Proteasome
activity was determined using proteasome assay buffer (Biomol) with Boc-LSTR-7-
AMC (Sigma), Suc-LLVY-AMC (Biomol) and Z-LLE-AMC (Biomol) as substrates for
the trypsin, chymotrypsin and caspase-like activities of the proteasome,
respectively. Data reflect kinetics of the linear phases of the curves of fluorigenic
substrate production measured with Cytofluor multiwell plate reader (Applied
Biosystems). The values from the same lysates treated with 10 mM MG132
correspond to non-proteasomal proteases and were subtracted to the proteasome
activity values.
Zebrafish model: maintenance of stocks and collection of
embryos. Wild-type zebrafish of the AB strain was reared under standard
conditions.39 Embryos were collected from natural spawnings, staged according to
established criteria 40 and reared in embryo medium (5 mM NaCl, 0.17 mM KCl,
0.33 mM CaCl2, 0.33 mM Mg2SO4, 10–5% Methylene Blue).
Zebrafish model: transient DNA overexpression. Injection solutions
were prepared using 100mg/ml of linearised plasmid DNA (either WTLRRK2,
GSLRRK2, LRRK1 or vector) with 50mg/ml of linearised plasmid UbG76V–GFP.
Approximately 2 nl of the injection solution was injected into the yolk of embryos at
the 1–2 cell stage. Embryos were viewed at regular intervals using an Olympus
SZX12 dissecting stereomicroscope (Olympus, Tokyo, Japan) under
epifluorescence with GFP filters. The number of embryos with mosaic GFP
expression was counted at regular intervals between 12 and 30 h.p.f. Digital images
were captured using an Olympus DP12 digital camera. For western blotting,
embryos were manually dechorionated and homogenised in lysis buffer then
processed as described above.
Statistics. In the case of flow cytometry, experiments were performed three
times independently in triplicates. Due to slightly different flow cytometer settings on
different days and different transfection efficiencies, fluorescence levels of control
cells vary largely between independent experiments. The statistical analysis of
independent data from different days is therefore difficult. Instead, we have
analysed the replicate data in each separate experiment by two-tailed, unpaired
Student’s t-test and shown P-values that are representative for all independent
experiments. In order to graphically display data of three independent experiments
in one combined graph, data of each separate experiment were normalised to the
mean of the respective control samples. The mean of all replicates was calculated
and is shown±S.D. of all replicates. In the case of immunocytochemnistry,
experiments were also performed three times in triplicates, and data are shown as
the means of three independent experiments±S.E.M. P-values were calculated by
unconditional logistical regression analysis using the general log linear analysis
option of SPSS version 6.1 software (IBM, Armonk, NY, USA). For the statistical
analysis of western blot data, two-tailed paired Student’s t-test was performed on
raw densitometry data from at least three independent experiments.
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